Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year OutlookBusiness Wire • 05/04/26
Evolus to Participate in the Needham 25th Annual Virtual Healthcare ConferenceBusiness Wire • 03/31/26
Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026Business Wire • 03/03/26
Evolus, Inc. (EOLS) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research • 02/24/26
Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026Business Wire • 02/17/26
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net RevenueBusiness Wire • 01/09/26
AMG Frontier Small Cap Growth Fund: Q3 Sees Strong Outperformance Across Semiconductor HoldingsSeeking Alpha • 12/15/25
Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research • 10/29/25
Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler LaunchPRNewsWire • 09/22/25
Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial OfficerBusiness Wire • 09/08/25
Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic BootcampBusiness Wire • 08/25/25
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel ProductBusiness Wire • 08/20/25